Cost & Insurance

Updated June 30, 2026 (launch day eve): Medicare Part D covers Foundayo, Wegovy, and Zepbound for weight loss starting July 1, 2026 via the Medicare GLP-1 Bridge program. Flat $50/month copay. 3.4 million beneficiaries eligible. Both oral pills (Foundayo and Wegovy tablet) are covered. Runs through Dec 31, 2027 (BALANCE Model Part D launch delayed indefinitely as of April 2026; Bridge extended to fill the gap).

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

Updated June 29, 2026: FDA issued 30 warning letters to telehealth companies June 15 for illegally marketing compounded GLP-1s. 503B permanent exclusion comment period extended to July 30, 2026 (from June 29 via FR 2026-12937). FDA proposed April 30 to permanently remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. 503A enforcement began April 22, 2025. 503B enforcement May 22, 2025. 3-4 million patients affected. Legal alternatives: compounded tirzepatide ($149-299/mo, medical-necessity only), Wegovy $349/mo via NovoCare, or Foundayo from $149/mo self-pay.

Updated June 11, 2026: CMS released the official prior authorization request form (cms.gov/glp-1-bridge.pdf, June 8) revealing a key eligibility nuance, beneficiaries with OSA, MASH, T2D, or established CVD are NOT eligible for the Bridge (they route through regular Part D instead). The Bridge is for weight-management-only patients. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. Prior auth via Humana/LI NET; requests not processed before July 1. Complete enrollment guide.

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25–$1,350/month. With insurance + savings card: $25/mo. Without insurance: $146/mo compounded sema (Yucca Health), $149/mo Foundayo pill, $299–449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo starting July 2026. Prices verified April 17, 2026 across 48 providers.

Verified April 2026: Tirzepatide costs $149/mo via Gala (compounded microdose), $299/mo via LillyDirect (brand Zepbound 2.5mg vial), $449/mo for LillyDirect 5mg+ vials, $25/mo with Zepbound savings card, or $1,086/mo retail list price. Full price breakdown with 47 verified providers.

Verified April 2026: Tirzepatide compounding enforcement began March 2025 after FDA removed it from the shortage list. Narrow medical-necessity exemptions still allow legal compounded tirzepatide at $149-300/mo (vs $1,086/mo retail Zepbound). Complete legal framework, safety, and verified pricing.

Verified April 2026: Zepbound savings card cuts copay to $25/fill ($1,300 max annual savings) with commercial insurance. Mounjaro savings card offers $25 copay for T2D. Both expire Dec 31, 2026. Activate in 2 minutes at zepbound.lilly.com/savings. Full eligibility + backup options.